PMID- 34206597
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240402
IS  - 2076-393X (Print)
IS  - 2076-393X (Electronic)
IS  - 2076-393X (Linking)
VI  - 9
IP  - 7
DP  - 2021 Jun 22
TI  - A Possible Role for HSV-1-Specific Humoral Response and PILRA rs1859788 
      Polymorphism in the Pathogenesis of Parkinson's Disease.
LID - 10.3390/vaccines9070686 [doi]
LID - 686
AB  - The etiology of Parkinson's disease (PD), a progressive nervous system disorder 
      that affects movement, is still unknown; both genetic and environmental factor 
      are believed to be involved in onset of the disease and its development. Herpes 
      simplex virus type 1 (HSV-1), in particular, is suspected to have a role in PD. 
      Paired Immunoglobulin-like type 2 receptor alpha (PILRA) is an inhibitory 
      receptor that down-regulates inflammation and is expressed on innate immune 
      cells. The PILRA rs1859788 polymorphism is protective against Alzheimer's 
      disease, even in relation with HSV-1 antibody titers, but no data are available 
      in PD. We analyzed HSV-1 antibody titers and PILRA rs1859788 in PD (n = 51) and 
      age-and sex-matched healthy controls (HC; n = 73). Results showed that HSV-1, but 
      not cytomegalovirus (CMV) or human herpes virus type 6 (HHV-6) antibody titers 
      were significantly higher in PD compared to HC (p = 0.045). The rs1859788 
      polymorphism was not differentially distributed between PD and HC, but the minor 
      allele A was more frequently carried by PD (68%) compared to HC (50%) (p = 0.06). 
      Notably, the rs1859788 minor allele A was statically more frequent in male PD 
      (65%) compared to male HC (37%) (p = 0.036). Finally, no relation was found 
      between HSV-1 antibody titers and PILRA genotype. Results herein suggest an 
      involvement of HSV-1 in PD and indicate a possible interaction between PILRA gene 
      polymorphisms and this neuropathology.
FAU - Agostini, Simone
AU  - Agostini S
AUID- ORCID: 0000-0002-6214-0645
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
FAU - Mancuso, Roberta
AU  - Mancuso R
AUID- ORCID: 0000-0002-4449-3623
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
FAU - Costa, Andrea S
AU  - Costa AS
AUID- ORCID: 0000-0002-7353-157X
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
FAU - Citterio, Lorenzo A
AU  - Citterio LA
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
FAU - Guerini, Franca R
AU  - Guerini FR
AUID- ORCID: 0000-0001-9461-5927
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
FAU - Meloni, Mario
AU  - Meloni M
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
FAU - Navarro, Jorge
AU  - Navarro J
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
FAU - Clerici, Mario
AU  - Clerici M
AUID- ORCID: 0000-0001-5920-6191
AD  - IRCCS Fondazione Don Carlo Gnocchi ONLUS, 20148 Milan, Italy.
AD  - Department of Pathophysiology and Transplantation, University of Milan, 20122 
      Milan, Italy.
LA  - eng
PT  - Journal Article
DEP - 20210622
PL  - Switzerland
TA  - Vaccines (Basel)
JT  - Vaccines
JID - 101629355
PMC - PMC8310311
OTO - NOTNLM
OT  - HSV-1
OT  - Parkinson's disease
OT  - antibody titers
OT  - paired immunoglobulin-like type 2 receptor alpha
OT  - rehabilitation
COIS- The authors declare no conflict of interest.
EDAT- 2021/07/03 06:00
MHDA- 2021/07/03 06:01
PMCR- 2021/06/22
CRDT- 2021/07/02 01:28
PHST- 2021/05/11 00:00 [received]
PHST- 2021/06/10 00:00 [revised]
PHST- 2021/06/17 00:00 [accepted]
PHST- 2021/07/02 01:28 [entrez]
PHST- 2021/07/03 06:00 [pubmed]
PHST- 2021/07/03 06:01 [medline]
PHST- 2021/06/22 00:00 [pmc-release]
AID - vaccines9070686 [pii]
AID - vaccines-09-00686 [pii]
AID - 10.3390/vaccines9070686 [doi]
PST - epublish
SO  - Vaccines (Basel). 2021 Jun 22;9(7):686. doi: 10.3390/vaccines9070686.